The research collaboration involves the preclinical application of ImmunoVaccine Technologies’s (IVT’s) DepoVax vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats.
Marc Mansour, vice president of R&D at IVT, said: “Because our DepoVax formulation creates a long-lasting immune response and comes in a dry format that is easily reconstituted, it is well suited for the development of an effective anti-anthrax vaccine.”